Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Age-Related Alterations Affecting the Chondrogenic Differentiation of Synovial Fluid Mesenchymal Stromal Cells in an Equine Model.

Mazzotti E, Teti G, Falconi M, Chiarini F, Barboni B, Mazzotti A, Muttini A.

Cells. 2019 Sep 20;8(10). pii: E1116. doi: 10.3390/cells8101116.

2.

New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia.

Paganelli F, Lonetti A, Anselmi L, Martelli AM, Evangelisti C, Chiarini F.

Adv Biol Regul. 2019 Sep 5:100649. doi: 10.1016/j.jbior.2019.100649. [Epub ahead of print]

PMID:
31523031
3.

Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.

Chiarini F, Evangelisti C, Lattanzi G, McCubrey JA, Martelli AM.

Biochim Biophys Acta Mol Cell Res. 2019 Aug;1866(8):1322-1337. doi: 10.1016/j.bbamcr.2019.03.013. Epub 2019 Mar 27. Review.

PMID:
30928610
4.

The Cutting Edge: The Role of mTOR Signaling in Laminopathies.

Chiarini F, Evangelisti C, Cenni V, Fazio A, Paganelli F, Martelli AM, Lattanzi G.

Int J Mol Sci. 2019 Feb 15;20(4). pii: E847. doi: 10.3390/ijms20040847. Review.

5.

Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation.

Ramazzotti G, Fiume R, Chiarini F, Campana G, Ratti S, Billi AM, Manzoli L, Follo MY, Suh PG, McCubrey J, Cocco L, Faenza I.

Adv Biol Regul. 2019 Jan;71:1-9. doi: 10.1016/j.jbior.2018.11.001. Epub 2018 Nov 5.

PMID:
30420274
6.

Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal.

Carli G, Farsi A, Chiarini F, Lippolis D, Cortellini G.

Eur Ann Allergy Clin Immunol. 2019 Jan;51(1):7-14. doi: 10.23822/EurAnnACI.1764-1489.80. Epub 2018 Nov 12. Review.

7.

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.

Evangelisti C, Chiarini F, McCubrey JA, Martelli AM.

Int J Mol Sci. 2018 Jun 26;19(7). pii: E1878. doi: 10.3390/ijms19071878. Review.

8.

Dual inhibition of PI3K/mTOR signaling in chemoresistant AML primary cells.

Bertacchini J, Frasson C, Chiarini F, D'Avella D, Accordi B, Anselmi L, Barozzi P, Forghieri F, Luppi M, Martelli AM, Basso G, Najmaldin S, Khosravi A, Rahim F, Marmiroli S.

Adv Biol Regul. 2018 May;68:2-9. doi: 10.1016/j.jbior.2018.03.001. Epub 2018 Mar 19.

PMID:
29576448
9.

Galactose-α-1,3-galactose syndrome: an Italian survey.

Villalta D, Cecchi L, Farsi A, Chiarini F, Minale P, Voltolini S, Scala E, Quercia O, Muratore L, Pravettoni V, Calamari AM, Cortellini G, Asero R.

Eur Ann Allergy Clin Immunol. 2017 Nov;49(6):263-269. doi: 10.23822/EurAnnACI.1764-1489.35.

10.

A revision of the Solanum elaeagnifolium clade (Elaeagnifolium clade; subgenus Leptostemonum, Solanaceae).

Knapp S, Sagona E, Carbonell AKZ, Chiarini F.

PhytoKeys. 2017 Aug 7;(84):1-104. doi: 10.3897/phytokeys.84.12695. eCollection 2017.

11.

Therapeutic targeting of CK2 in acute and chronic leukemias.

Buontempo F, McCubrey JA, Orsini E, Ruzzene M, Cappellini A, Lonetti A, Evangelisti C, Chiarini F, Evangelisti C, Barata JT, Martelli AM.

Leukemia. 2018 Jan;32(1):1-10. doi: 10.1038/leu.2017.301. Epub 2017 Sep 27. Review.

12.

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.

Evangelisti C, Cappellini A, Oliveira M, Fragoso R, Barata JT, Bertaina A, Locatelli F, Simioni C, Neri LM, Chiarini F, Lonetti A, Buontempo F, Orsini E, Pession A, Manzoli L, Martelli AM, Evangelisti C.

J Cell Physiol. 2018 Mar;233(3):1796-1811. doi: 10.1002/jcp.26135. Epub 2017 Sep 7.

PMID:
28777460
13.

Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.

Masetti R, Bertuccio SN, Astolfi A, Chiarini F, Lonetti A, Indio V, De Luca M, Bandini J, Serravalle S, Franzoni M, Pigazzi M, Martelli AM, Basso G, Locatelli F, Pession A.

J Hematol Oncol. 2017 Jan 21;10(1):26. doi: 10.1186/s13045-017-0396-0.

14.

Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.

Evangelisti C, Evangelisti C, Buontempo F, Lonetti A, Orsini E, Chiarini F, Barata JT, Pyne S, Pyne NJ, Martelli AM.

Leukemia. 2016 Nov;30(11):2142-2151. doi: 10.1038/leu.2016.208. Epub 2016 Jul 27. Review.

15.

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.

Lonetti A, Cappellini A, Bertaina A, Locatelli F, Pession A, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, Zambonin L, Neri LM, Martelli AM, Chiarini F.

J Hematol Oncol. 2016 Oct 24;9(1):114.

16.

Risk assessment of maize damage by wireworms (Coleoptera: Elateridae) as the first step in implementing IPM and in reducing the environmental impact of soil insecticides.

Furlan L, Contiero B, Chiarini F, Colauzzi M, Sartori E, Benvegnù I, Fracasso F, Giandon P.

Environ Sci Pollut Res Int. 2017 Jan;24(1):236-251. doi: 10.1007/s11356-016-7692-z. Epub 2016 Oct 6.

17.

Rapid desensitization to anakinra-related delayed reaction: Need for a standardized protocol.

Emmi G, Silvestri E, Cantarini L, Lopalco G, Cecchi L, Chiarini F, Farsi A.

J Dermatol. 2017 Aug;44(8):981-982. doi: 10.1111/1346-8138.13619. Epub 2016 Sep 26. No abstract available.

PMID:
27667671
18.

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.

Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, Bertacchini J, Neri LM, McCubrey JA, Martelli AM.

Oncotarget. 2016 Jan 12;7(2):1323-40. doi: 10.18632/oncotarget.6361.

19.

Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.

Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA, Martelli AM.

Biochim Biophys Acta. 2016 Mar;1863(3):449-463. doi: 10.1016/j.bbamcr.2015.08.015. Epub 2015 Sep 1. Review.

20.

PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.

Lonetti A, Cappellini A, Spartà AM, Chiarini F, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, McCubrey JA, Martelli AM.

Oncotarget. 2015 Apr 30;6(12):10399-414.

21.

Current treatment strategies for inhibiting mTOR in cancer.

Chiarini F, Evangelisti C, McCubrey JA, Martelli AM.

Trends Pharmacol Sci. 2015 Feb;36(2):124-35. doi: 10.1016/j.tips.2014.11.004. Epub 2014 Dec 11. Review.

PMID:
25497227
22.

Autophagy in acute leukemias: a double-edged sword with important therapeutic implications.

Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Neri LM, McCubrey JA, Martelli AM.

Biochim Biophys Acta. 2015 Jan;1853(1):14-26. doi: 10.1016/j.bbamcr.2014.09.023. Epub 2014 Oct 2. Review.

23.

Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics.

Evangelisti C, Evangelisti C, Teti G, Chiarini F, Falconi M, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Beak DJ, Bittman R, Pyne S, Pyne NJ, Martelli AM.

Oncotarget. 2014 Sep 15;5(17):7886-901.

24.

PLCβ1a and PLCβ1b selective regulation and cyclin D3 modulation reduced by kinamycin F during k562 cell differentiation.

Bavelloni A, Dmitrienko GI, Goodfellow VJ, Ghavami A, Piazzi M, Blalock W, Chiarini F, Cocco L, Faenza I.

J Cell Physiol. 2015 Mar;230(3):587-94. doi: 10.1002/jcp.24776.

PMID:
25160985
25.

Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).

Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Bressanin D, Cappellini A, Orsini E, McCubrey JA, Martelli AM.

Int J Oncol. 2014 Sep;45(3):909-18. doi: 10.3892/ijo.2014.2525. Epub 2014 Jun 26. Review.

PMID:
24968804
26.

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.

Spartà AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM.

Cell Cycle. 2014;13(14):2237-47. doi: 10.4161/cc.29267. Epub 2014 May 29.

27.

Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.

Martelli AM, Lonetti A, Buontempo F, Ricci F, Tazzari PL, Evangelisti C, Bressanin D, Cappellini A, Orsini E, Chiarini F.

Adv Biol Regul. 2014 Sep;56:6-21. doi: 10.1016/j.jbior.2014.04.004. Epub 2014 Apr 30. Review.

PMID:
24819383
28.

MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.

Astolfi A, Vendemini F, Urbini M, Melchionda F, Masetti R, Franzoni M, Libri V, Serravalle S, Togni M, Paone G, Montemurro L, Bressanin D, Chiarini F, Martelli AM, Tonelli R, Pession A.

Oncotarget. 2014 Jan 15;5(1):120-30.

29.

Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.

Lonetti A, Antunes IL, Chiarini F, Orsini E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Barata JT, Martelli AM.

Leukemia. 2014 Jun;28(6):1196-206. doi: 10.1038/leu.2013.369. Epub 2013 Nov 6.

PMID:
24310736
30.

Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, Barata JT, Martelli AM.

Leukemia. 2014 Mar;28(3):543-53. doi: 10.1038/leu.2013.349. Epub 2013 Nov 20.

PMID:
24253024
31.

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia.

Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Spartà A, McCubrey JA, Martelli AM.

Expert Opin Ther Targets. 2013 Aug;17(8):921-36. doi: 10.1517/14728222.2013.808333. Epub 2013 Jun 11. Review.

PMID:
23755894
32.

Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients.

Martelli AM, Lonetti A, Amadori S, McCubrey JA, Chiarini F.

Cell Cycle. 2013 Jun 15;12(12):1815-6. doi: 10.4161/cc.25117. Epub 2013 May 24. No abstract available.

33.

K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway.

Poli A, Faenza I, Chiarini F, Matteucci A, McCubrey JA, Cocco L.

Cell Cycle. 2013 Jun 1;12(11):1713-21. doi: 10.4161/cc.24806. Epub 2013 May 6.

34.

Advances in targeting signal transduction pathways.

McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN.

Oncotarget. 2012 Dec;3(12):1505-21. Review.

35.

An epidemiological survey of Mycoplasma hominis and Ureaplasma urealyticum in gynaecological outpatients, Rome, Italy.

Verteramo R, Patella A, Calzolari E, Recine N, Marcone V, Osborn J, Chiarini F, Degener AM.

Epidemiol Infect. 2013 Dec;141(12):2650-7. doi: 10.1017/S0950268813000277. Epub 2013 Feb 28.

PMID:
23445723
36.

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.

Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA, Martelli AM.

Oncotarget. 2012 Dec;3(12):1615-28.

37.

Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin: a Therapeutic Strategy for Acute Leukemias.

Chiarini F, Evangelisti C, Buontempo F, Bressanin D, Fini M, Cocco L, Cappellini A, McCubrey JA, Martelli AM.

Curr Cancer Drug Targets. 2012 Nov 21. [Epub ahead of print]

PMID:
23215723
38.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM.

Oncotarget. 2012 Oct;3(10):1068-111. Review.

39.

Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.

Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Steelman LS, McCubrey JA.

Adv Biol Regul. 2013 Jan;53(1):146-55. doi: 10.1016/j.jbior.2012.09.004. Epub 2012 Sep 16. No abstract available.

PMID:
23073564
40.

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM.

Oncotarget. 2012 Sep;3(9):954-87. Review.

41.

Polyomavirus BK infection before liver transplantation in patients with chronic kidney disease.

Mitterhofer AP, Tinti F, Umbro I, Pietropaolo V, Fiacco F, Bellizzi A, Anzivino E, Ginanni Corradini S, Poli L, Rossi M, Berloco PB, Ferretti G, Chiarini F, Taliani G.

Transplant Proc. 2012 Sep;44(7):1934-7. doi: 10.1016/j.transproceed.2012.06.052.

PMID:
22974876
42.

Polyomavirus BK infection in end-stage renal disease: analysis of viral replication in patients on hemodialysis or peritoneal dialysis.

Mitterhofer AP, Umbro I, Pietropaolo V, Meçule A, Russo GE, Tinti F, Fiacco F, Poli L, Bellizzi A, Anzivino E, Ferretti G, Berloco PB, Chiarini F, Taliani G.

Transplant Proc. 2012 Sep;44(7):1869-72. doi: 10.1016/j.transproceed.2012.06.021.

PMID:
22974858
43.

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA, Martelli AM.

Oncotarget. 2012 Aug;3(8):811-23.

44.

Epidemiology of Chlamydia trachomatis endocervical infection in a previously unscreened population in Rome, Italy, 2000 to 2009.

Marcone V, Recine N, Gallinelli C, Nicosia R, Lichtner M, Degener AM, Chiarini F, Calzolari E, Vullo V.

Euro Surveill. 2012 Jun 21;17(25). pii: 20203.

45.

Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a.

Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA, Martelli AM.

Cell Cycle. 2012 Jul 1;11(13):2467-75. doi: 10.4161/cc.20859. Epub 2012 Jul 1.

PMID:
22713244
46.

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.

Martelli AM, Chiarini F, Evangelisti C, Ognibene A, Bressanin D, Billi AM, Manzoli L, Cappellini A, McCubrey JA.

Expert Opin Ther Targets. 2012 Jul;16(7):729-42. doi: 10.1517/14728222.2012.694869. Epub 2012 Jun 12. Review.

PMID:
22686561
47.

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM.

Leukemia. 2012 Nov;26(11):2336-42. doi: 10.1038/leu.2012.136. Epub 2012 May 22.

PMID:
22614243
48.

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA.

Oncotarget. 2012 Apr;3(4):371-94. Review.

49.

Reactivation of human polyomavirus JC in patients affected by psoriasis vulgaris and psoriatic arthritis and treated with biological drugs: preliminary results.

Nardis C, Anzivino E, Bellizzi A, Rodio DM, De Pità O, Chiarini F, Pietropaolo V.

J Cell Physiol. 2012 Dec;227(12):3796-802. doi: 10.1002/jcp.24089.

PMID:
22422468
50.

Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Bellizzi A, Nardis C, Anzivino E, Rodìo D, Fioriti D, Mischitelli M, Chiarini F, Pietropaolo V.

J Neurovirol. 2012 Feb;18(1):1-11. doi: 10.1007/s13365-012-0080-7. Review.

PMID:
22290500

Supplemental Content

Loading ...
Support Center